Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM45NHF)

• Drug Name: RTR-003632 Drug Info
• Synonyms: Acetates; Acetic acid,phenyl ester; Phenyl acetate; Acetoxybenzene; Acetyl phenol; Acetylphenol; Fenylester kyseliny octove; IPBVNPXQWQGGJP-UHFFFAOYSA-N; PHENYL ACETATE; Phenol acetate; Phenyl acetate, 97%; Phenyl acetate, 99%; Phenyl ester of acetic acid; phenoxy ethan-1-one; (Acetyloxy)benzene; 122-79-2; 355G9R500Y; AI3-01972; Acetic acid phenyl ester; Acetic acid, phenyl ester; BRN 0636458; CHEBI:8082; EINECS 204-575-0; Fenylester kyseliny octove [Czech]; HSDB 2667; MFCD00008699; NSC 27795; PhOAc; UNII-355G9R500Y; acetic acid phenyl
• Cross-matching ID:
  PubChem CID: 31229
  ChEBI ID: CHEBI:8082
  CAS Number: CAS 122-79-2
  TTD Drug ID: DM45NHF
  INTEDE Drug ID: DR2016

Molecule-Related Drug Atlas

Drug(s) Metabolized By Serum paraoxonase/arylesterase 1 (PON1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Loteprednol Etabonate	DM8QTJI	Eye inflammation	9A02	Approved	[5]
Prulifloxacin	DMOK965	Urinary tract infection	GC08	Approved	[6]
PARAOXON	DMN4ZKC	Discovery agent	N.A.	Investigative	[1]
gamma-butyrolactone	DMDCZWY	Discovery agent	N.A.	Investigative	[1]
Coumaranone	DM7TCPG	N. A.	N. A.	Investigative	[1]
Dihydrocoumarin	DMGLX1R	N. A.	N. A.	Investigative	[1]
Gamma-thiobutyrolactone	DM83HUI	N. A.	N. A.	Investigative	[1]
Homogentisic acid	DMQD0YW	N. A.	N. A.	Investigative	[1]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[8]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[9]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[10]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[11]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[12]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[13]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[14]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[15]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[7]

Drug(s) Affected By Serum paraoxonase/arylesterase 2 (PON2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[16]
Selenium	DM25CGV	N. A.	N. A.	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[19]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[23]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[24]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[25]

Drug(s) Affected By Serum paraoxonase/lactonase 3 (PON3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[26]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[27]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[28]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[25]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[26]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[26]
Phenylacetic acid	DMQ95GE	Hepatic encephalopathy	DB99.5	Approved	[30]

Drug(s) Affected By Neurabin-1 (PPP1R9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[31]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[33]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[34]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[22]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[35]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[36]

Drug(s) Affected By Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[37]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[38]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[39]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[40]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[41]
Succinylcholine	DM2ET1M	Plasma cell myeloma	2A83.1	Approved	[42]
Ethopropazine	DM0N3L7	Parkinson disease	8A00.0	Approved	[38]
Dimenhydrinate	DM264B3	Meniere disease	AB31.0	Approved	[43]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[44]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[43]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Serum paraoxonase/arylesterase 1 (PON1) Main DME	DESDN74	PON1_HUMAN	Substrate	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Biotransformations	[2]
Neurabin-1 (PPP1R9A)	OTJL2TOC	NEB1_HUMAN	Biotransformations	[3]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Biotransformations	[4]
Serum paraoxonase/arylesterase 2 (PON2)	OT55NCTD	PON2_HUMAN	Biotransformations	[3]
Serum paraoxonase/lactonase 3 (PON3)	OT80W9TA	PON3_HUMAN	Biotransformations	[3]

References

• [1] Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
• [2] Time-course of human cholinesterases-catalyzed competing substrate kinetics. Chem Biol Interact. 2019 Sep 1;310:108702. doi: 10.1016/j.cbi.2019.06.015. Epub 2019 Jun 24.
• [3] Effects of PON polymorphisms and haplotypes on molecular phenotype in Mexican-American mothers and children. Environ Mol Mutagen. 2011 Mar;52(2):105-16. doi: 10.1002/em.20567.
• [4] Polyethylene glycosylation prolongs the stability of recombinant human paraoxonase-1. Toxicol Lett. 2012 May 5;210(3):366-71. doi: 10.1016/j.toxlet.2012.02.019. Epub 2012 Mar 5.
• [5] Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89.
• [6] Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
• [7] Antiepileptic drugs: impacts on human serum paraoxonase-1. J Biochem Mol Toxicol. 2017 Jun;31(6).
• [8] Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem J. 2003 Oct 15;375(Pt 2):275-85.
• [9] Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin Endocrinol (Oxf). 2004 Jan;60(1):75-80.
• [10] Effects of some antibiotics on paraoxonase from human serum in vitro and from mouse serum and liver in vivo. Biol Pharm Bull. 2006 Aug;29(8):1559-63.
• [11] Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2083-9. doi: 10.1161/01.ATV.0000096207.01487.36. Epub 2003 Sep 18.
• [12] Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol. 2004 Jun;24(12):5209-22.
• [13] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [14] Transcriptional regulation of human paraoxonase 1 by PXR and GR in human hepatoma cells. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):348-54.
• [15] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [16] Paraoxonase enzyme protects retinal pigment epithelium from chlorpyrifos insult. PLoS One. 2014 Jun 30;9(6):e101380. doi: 10.1371/journal.pone.0101380. eCollection 2014.
• [17] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [18] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [19] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [20] Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):175-80. doi: 10.1161/01.ATV.0000104011.88939.06. Epub 2003 Oct 30.
• [21] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [22] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [23] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [24] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [25] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [26] Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005 Jun;46(6):1239-47. doi: 10.1194/jlr.M400511-JLR200. Epub 2005 Mar 16.
• [27] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [28] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [29] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [30] Cloning, high level expression of human paraoxonase-3 in Sf9 cells and pharmacological characterization of its product. Biochem Pharmacol. 2005 Oct 1;70(7):1019-25. doi: 10.1016/j.bcp.2005.07.004.
• [31] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [32] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [33] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [34] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [35] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [36] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [37] Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
• [38] Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
• [39] Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
• [40] Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
• [41] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [42] Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
• [43] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [44] Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.